Scripps 15th Annual Structural Heart Intervention and Imaging 2026

1. Overview
The Scripps 15th Annual Structural Heart Intervention and Imaging 2026 course provides a rigorous, deep-dive into the latest advancements in structural heart disease management. The program focuses on cutting-edge transcatheter therapies (TEER, TAVR, TTVR), advanced 3D ICE and TEE procedural guidance, stroke prevention strategies (LAAO), and complex case management, equipping practitioners with techniques to optimize patient selection and procedural safety.
Course Date: Thursday, February 12, 2026: 7:30 a.m.-6 p.m. Friday, February 13, 2026: 7:30 a.m.-3 p.m.
The Scripps Structural Heart Intervention and Imaging course delivers a practical, state-of-the-art, live case-based review of structural heart disease interventions and cardiovascular imaging. Emphasizing multidisciplinary collaboration, the program features expert faculty, including interventional cardiologists, echocardiologists, electrophysiologists, cardiothoracic surgeons, anesthesiologists, and sonographers. The course will cover clinical guidelines on patient selection, pre-procedural evaluation, procedural techniques, imaging integration, and challenges, concluding with outcome assessments and future innovations in the field.
2. Learning Objectives
Upon completion of this activity, participants should be able to:

Build and optimize a multidisciplinary team of health care professionals to ensure appropriate management of patients with structural heart disease.
Identify the equipment and imaging technologies necessary to perform structural heart disease interventions.
Apply a comprehensive approach to the assessment of the aortic, mitral, and tricuspid valves, the interatrial septum, and the left and right ventricles, using echocardiography (TTE, TEE, and ICE), CT, and MRI for the purpose of the interventional treatment of these cardiac structures.
Outline the current indications for LAA closure, PFO closure, transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), and mitral transcatheter edge to edge repair (TEER).
Evaluate echocardiographic and CT imaging before and after LAA closure, and identify and measure peri-device leaks, device-related thrombus, and other potential complications.
Identify appropriate treatment strategies for patients with mitral valve disease (i.e., TEER or TMVR) or tricuspid valve disease (i.e., TEER or TTVR) based upon imaging findings.
Incorporate live TEE multiplanar imaging to optimize transcatheter mitral and tricuspid valve intervention.
Apply 2D and 4D ICE during structural heart intervention.
Recognize the risk of left ventricular outflow tract obstruction after TMVR and coronary occlusion after TAVR and apply specific interventional strategies to prevent them (e.g., LAMPOON and BASILICA).
Integrate emerging data regarding surgical risk, including low and intermediate-risk patients into TAVR decision-making.
Recognize heart failure patients who might benefit from novel interventional strategies, such as interatrial shunt devices, to improve symptoms.
Optimize the anesthetic management of patients with reduced ejection fraction undergoing TEER or TMVR.
Employ best practices to safely manage potential complications of catheter-based therapies for structural heart disease.

3. Target Audience

Best for interventional cardiologists, echocardiographers, and cardiac surgeons who want advanced training in structural heart interventions and imaging.

4. Topics

01 San Diego Transcatheter Edge-to-Edge Repair Conclave

02 Best Practices for T-TEER Procedural Strategy

03 Getting off the Struggle Bus During TEE Imaging How to Acquire the Key Views When Imaging is Challenging

04 M-TEER Beyond A2-P2 Key Techniques to Address Near-Commissural Jets

05 Invited T-TEER Case Presentation from San Diego Operator Imaging Team, with Panel Discussion Arvin Narula, MD

06 Invited T-TEER Case Presentation from San Diego Operator Imaging Team, with Panel Discussion Ryan Reeves, MD

07 New Frontiers in MR and TR Treatment PASCAL Precision System Predictability and the Era of EVOQUE TTVR Amr Mohsen, MD

08 LIVE CASE FROM SCRIPPS CLINIC

09 Clinical-Pathological Correlations The Left Atrial Appendage

10 TEE vs. 3D ICE for LAAO Procedural Guidance Strengths, Weaknesses, and How to Choose

11 Interpreting CT Imaging After LAAO Leaks, HALT, DRT, and Device Position

12 LAAO Is Safe Until It’s Not Untoward Events During and After the Procedure and How to Prevent Them

13 Managing Peri-Device Leak Who to Treat and Technically How to Do It VIDEO PDF NOT RELEASE

14 LIVE CASE FROM SCRIPPS CLINIC

15 Clinical-Pathological Correlations The Right Ventricle

16 Current State-of-the-Art to Assess Right Ventricular Function by TTE, CT, and MRI

17 Managing RV Function Before and After Tricuspid Intervention

18 Atrial Functional MR Identification, Mechanism of Action, and Potential Treatments

19 Lead-ing into Trouble How to Identify Lead-tricuspid Leaflet Interaction

20 CHAMPIONing Watchman FLX as a Front-line Treatment OPTION for AF Stroke Prevention

21 What’s the Optimal Post-Procedure Medication Regiment after Watchman FLX PRO

22 Addressing Unmet Needs in LAAC with Watchman Next Generation (NG)

23 LIVE CASE FROM SCRIPPS CLINIC

24 Clinical-Pathological Correlations The Mitral Valve

25 Cutting Edge Assessment of Mitral Regurgitation in 2026 Quantification, Mechanism, and Localization of Pathology

26 Mitral TEER for Moderate MR Current Data and Future Directions

27 Deep Dive and Clinical Implications of the ENCIRCLE Trial Patient Selection and Technique for Balloon-Expandable-in-Dock TMVR

28 Advanced Techniques to Prevent LVOTO After Mitral Valve-in-Valve Implantation

29 LIVE CASE FROM SCRIPPS CLINIC

30 Concomitant LAA Closure and Mitral TEER Current Evidence and Procedural Considerations

31 Interatrial Shunts for HFpEF and HFrEF Device and Data Update

32 Imaging for Transseptal Puncture to Optimize Safety and Procedural Success

33 Aortic Insufficiency Imaging Evaluation and Indications for Intervention

34 Dedicated TAVI for Aortic Insufficiency Has Arrived Patient Selection, Technology, and Procedural Technique

35 Contemporary Outcomes Data with Amulet and the Next Big Randomized Trial A CATALYST for Change

36 Next-Generation Device, Next Generation Results Amulet 360 and the VERITAS Study

37 Optimizing Procedural Outcomes and Safety Case Examples of Amulet LAAO

38 Current State-of-the-art and Unmet Clinical Needs for the Treatment of Aortic Regurgitation

39 Imaging for Aortic Regurgitation From Diagnosis to Patient Selection

40 Transcatheter Intervention for Aortic Regurgitation Emerging Technologies, Clinical Trial Data, and Case Examples

41 LIVE CASE FROM SCRIPPS CLINIC

42 Clinical-Pathological Correlations The Tricuspid Valve

43 Cutting Edge Assessment of the Tricuspid Valve by Echo Imaging Part I TR Quantification and Mechanisms of Action

44 Tricuspid Surgery for TR Technique, Outcomes, and Lessons Learned for the Transcatheter Experience

45 Cutting Edge Assessment of the Tricuspid Valve by Echo Imaging Part II Screening for T-TEER and TTVR

46 Cerebral Protection for TAVR in 2026 How to Apply the Latest Data to Your Practice

47 LIVE CASE FROM SCRIPPS CLINIC

48 Optimizing T-TEER Outcomes How to Identify the Right (and Wrong) Patient

49 Insertion, Insertion, Insertion Imaging Strategies to Confirm Leaflet Grasping During T-TEER

50 Optimizing TTVR Outcomes How to Identify the Right (and Wrong) Patient

51 Hands Off the Valve! The Role of Caval Valve Implantation (CAVI) in Severe TR

52 Keys to Enhance Procedural Safety During TTVR

53 The Value Proposition for Verisight Pro 3D ICE Synergizing Hospital, Patient, and Operator Needs

54 Getting off the Struggle Bus Verisight Pro 3D ICE for Tricuspid Transcatheter Edge-to-Edge Repair

55 Verisight Pro 3D ICE Guided LAAO Under Conscious Sedation The Present and Future for Stroke Prevention in AF Patients

56 Stop Spinning to Nowhere Using Verisight Pro 3D ICE for Evoque TTVR

57 LIVE CASE FROM SCRIPPS CLINIC

58 Clinical-Pathological Correlations The Aortic Valve

59 TAVR in 2026 Where Are We and Where Are We Going

60 Procedural Planning for Lifetime TAVI Management and Lessons from Past Mistakes

61 Leaflet Modification to Prevent Coronary Obstruction After TAVR Patient Selection and Technical Approach VIDEO PDF NOT RELEASE

62 Contemporary TAVR for Bicuspid Aortic Valves